Table 2.
Phase | Regimens | Patients | ORR (%) | PFS (months) | OS (months) | References |
---|---|---|---|---|---|---|
I | Crizotinib | 149 | 60.8 | 9.7 | Not achieved | 79,89 |
II | Crizotinib | 261 | 59.8 | 8.1 | Not achieved | 91 |
III | Crizotinib | 172 | 65.7 | 7.7 | 20.3 | 90 |
Docetaxel | 72 | 6.9 | 2.6 | 22.8 | ||
Pemetrexed | 99 | 29.3 | 4.2 |
Abbreviations: PFS, progression-free survival; OS, overall survival; ORR, objective response rate.